Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teicoplanin versus vancomycin for initial empiric treatment of febrile neutropenia at high risk for gram-positive infection
2014-004628-23Phase 4
- Sponsor
- Sanofi
- Start
- Mar 2015
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Gram-positive bacterial infection and febrile neutropenia (FN) comparing Targocid arm with Vancomycin arm (2 arms). Primary endpoint: Number of subjects according to treatment response.
02
Drugs
teicoplaninvancomycin
03
Conditions
Gram-positive bacterial infectionfebrile neutropenia (FN)
Beyond the preview
Go deeper on 2014-004628-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004628-23.